At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
everolimus +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2 Study of Imatinib in Combination With Everolimus in Synovial Sarcoma
In Brief
A Phase 2 clinical trial evaluating diagnostic laboratory biomarker analysis, everolimus, and 1 other intervention for Adult Synovial Sarcoma and 3 related conditions. Completed, enrolled 14 participants across 1 site.
Detailed Summary
This phase I/II clinical trial is studying the side effects and best dose of everolimus when given with imatinib mesylate and to see how well they work in treating patients with locally advanced, locally recurrent or metastatic soft tissue sarcoma. Everolimus and imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Synovial Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2011
First PostedJan 2011
Primary CompletionOct 2013
TodayJul 2026
First PostedJan 24, 2011
Enrollment StartJan 1, 2011
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 15.4 years ago
Interventions
diagnostic laboratory biomarker analysisother
Correlative studies
everolimusdrug
Given PO
imatinib mesylatedrug
Given PO